Sellas Life Sciences Group
Biotechnology, , New York, United States, 11-50 Employees
Phone Number: 16*********
Who is SELLAS LIFE SCIENCES GROUP
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS lead product candidate, galinpepimut-S (GPS), ...
Read More
-
Headquarters: New York, New York, United States
-
Date Founded: 2012
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from SELLAS LIFE SCIENCES GROUP
SELLAS Life Sciences Group Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding SELLAS Life Sciences Group
Answer: SELLAS Life Sciences Group's headquarters are located at New York, United States
Answer: SELLAS Life Sciences Group's phone number is 16*********
Answer: SELLAS Life Sciences Group's official website is https://sellaslifesciences.com
Answer: SELLAS Life Sciences Group's revenue is $1 Million to $5 Million
Answer: SELLAS Life Sciences Group has 11-50 employees
Answer: SELLAS Life Sciences Group is in Biotechnology
Answer: SELLAS Life Sciences Group contact info: Phone number: 16********* Website: https://sellaslifesciences.com
Answer: We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month